Pregnancy-related cell traffic, microchimerism and autoimmunity: The possibility of reducing autoimmune disease prevalence

Expert Review of Obstetrics and Gynecology

Volumn 2, Issue 3, 2007, Pages 341-345

  Gleicher, Norbert ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

autoimmunity; microchimerism; pregnancy related cell traffic; rheumatology

Indexed keywords

EID: 39049133337     PISSN: 17474108     EISSN: 17474116     Source Type: Journal    
DOI: 10.1586/17474108.2.3.341     Document Type: Article

References (41)

1. Bianchi DW, Romero R. Biological implications of bi-directional fetomaternal cell traffic: a summary of a National Institute of Child Health and Human Development-sponsored conference. J. Matern. Fetal Neonatal Med. 14, 123–129 (2003).
2. Adams KM, Nelson JL. Microchimerism. An investigative frontier in autoimmunity and transplantation. JAMA 291, 1127–1131 (2004).
3. Maloney S, Smith A, Furst DE et al. Microchimerism of maternal origin persists into adult life. J. Clin. Invest. 104, 41–47 (1999).
4. Aractingi S, Berkane N, Betheau P et al. Fetal DNA in skin of polymorphic eruptions of pregnancy. Lancet 352, 1898–1901 (1998).
5. Artlett CM, Smith B, Jimenez SA. Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N. Engl. J. Med. 338, 1186–1191 (1998).
6. Ohtsuka T, Miyamoto Y, Yamakage A, Yamazaki S. Quantitative analysis of microchimerism in systemic sclerosis skin tissue. Arch. Dermatol. Res. 293, 387–391 (2001).
7. Johnson K, Nelson JL, Furst DE et al. Fetal cell microchimerism in multiple tissues from multiple sites in women with systemic sclerosis. Arthritis Rheum. 44, 1848–1854 (2001).
8. Srivatsa B, Srivatsa S, Johnson KL, Samura O, Lee SL, Bianchi DW. Microchimerism of presumed fetal origin in thyroid specimens from women: a case control study. Lancet 358, 2034–2038 (2001).
9. Nelson JL. Microchimerism and autoimmune disease. N. Engl. J. Med. 338, 1224–1225 (1998).
10. Turco AE, Bambara LM. Pregnancy, microchimerism and autoimmunity: an update. Lupus 13, 659–660 (2004).
11. Stevens AM, Hermes HM, Rutlege JC, Buyon JP, Nelson JL. Myocardial-tissue- specific phenotype of maternal microchimerism in neonatal lupus congenital heart block. Lancet 362, 1617–1623 (2003).
12. Christner PJ, Artlett CM, Conway RF, Jimenez SA. Increased numbers of microchimeric cells of fetal origin are associated with dermal fibrosis in mice following injection of vinyl chloride. Arthritis Rheum. 43, 2598–2605 (2000).
13. Walsh JP, Bremner AP, Bulsara MK et al. Parity and the risk of autoimmune thyroid disease: a community based study. J. Clin. Endocrinol. Metab. 90, 5309–5312 (2005).
14. Gannage M, Amoura Z, Lantz O, Piette JC, Caillat Zucman S. Feto-maternal microchimerism in connective tissue diseases. Eur. J. Immunol. 32, 3405–3413 (2002).
15. Kaneda T, Shiraki K, Hirano K, Nagata I. Detection of maternal fetal transfusion by placental alkaline phosphatase levels. J. Pediatr. 111, 877–881 (1997).
16. Nelson JL, Hughes KA, Smith AG, Nisperos BB, Branchaud AM, Hansen JA. Maternal–fetal disparity in HLA class II alloantigens and the pregnancy-induced amelioration of rheumatoid arthritis. N. Engl. J. Med. 329, 466–471 (1993).
17. Evans PC, Lamber N, Maloney S, Furst DE, Moore JM, Nelson JL. Long-term fetal microchimerism in peripheral blood mononuclear cell subsets in healthy women and in women with scleroderma. Blood 93, 2033–2037 (1999).
18. Starzl TE, Demetri AJ, Trucco M et al. Chimerism after liver transplantation for type IV glycogen storage disease and type I Gaucher disease. N. Engl. J. Med. 328, 745–749 (1993).
19. Artlett CM, Ramos R, Jiminez SA, Patterson K, Miller FW, Rider LG. Chimeric cells of maternal origin in juvenile idiopathic inflammatory myopathies. Childhood Myositis Heterogeneity Collaborative Group. Lancet 356, 2155–2156 (2000).
20. Srivatsa B, Srivatsa S, Johnson KL, Bianchi DW. Maternal cell microchimerism in newborn tissues. J. Pediatrics 142, 31–35 (2003).
21. Al-Mufti R, Hambley H, Albaiges G, Lees C, Nicolaides KH. Increased fetal erythroblasts in women who subsequently develop pre-eclampsia. Hum. Reprod. 15, 1624–1628 (2000).
22. Lo DYM, Leung TN, Tein MSC et al. Qualitative abnormalities of fetal DNA in maternal serum in preeclampsia. Clin. Chemistry 45, 184–188 (1999).
23. Zhong XY, Laivuori H, Livingston JC et al. Elevation of both maternal and fetal extracellular circulating deoxyribonucleic acid concentrations in plasma of pregnant women with preeclampsia. Am. J. Obstet. Gynecol. 184, 414–419 (2001).
24. Gleicher N. Why much of the pathophysiology of preeclampsia/eclampsia has to be “autoimmune” in nature. Am. J. Obstet. Gynecol. 196, 5.e1–5.e7 (2007).
25. Rose CH, Thigpen BD, Bofill JA, Cushman J, May WL, Martin JN Jr. Obstetric implications of antepartum corticosteroid therapy for HELLP syndrome. Obstet. Gynecol. 104, 1011–1014 (2004).
26. Farina A, LeShane ES, Romero R et al. High levels of fetal cell-free DNA in maternal serum: a risk factor for spontaneous preterm delivery. Am. J. Obstet. Gynecol. 193, 421–425 (2005).
27. El-Roeiy A, Myers SA, Gleicher N. The relationship between autoantibodies and intrauterine growth retardation in hypertensive disorders of pregnancy. Am. J. Obstet. Gynecol. 164, 1253–1261 (1991).
28. Yamamoto T, Yoshimura S, Geshi Y et al. Measurement of antiphospholipid antibody by ELISA using purified β-2-glycoprotein I in preeclampsia. Immunology 94, 196–200 (1993).
29. Sheiner E, Ohel I, Levy A, Katz M. Pregnancy outcome in women with pruritus gravidarum. J. Reprod. Med. 51, 394–398 (2006).
30. Gleicher N, Pratt D, Dudkiewicz A. What do we really know about autoantibody abnormalities and reproductive failure: a critical review. Autoimmunity 16, 115–140 (1993).
31. Bianchi DW, Farina A, Weber W et al. Significant fetal–maternal hemorrhage after termination of pregnancy: implications for development of fetal cell microchimerism. Am. J. Obstet. Gynecol. 184, 703–706 (2001).
32. Davis AT. Clinical review 160: postpartum autoimmune thyroid disease: the potential role of fetal microchimerism. J. Clin. Endocrinol. Metab. 88, 2965–2971 (2003).
33. Renne C, Ramos-Lopez E, Steimle-Grauer SA et al. Thyroid fetal male microchimerism in mothers with thyroid disorders: presence of Y-chromosomal immunofluorescence in thyroid-infiltrating lymphocytes is more prevalent in Hashimoto’s thyroiditis and Grave’s disease than in follicular adenomas. J. Clin. Endocrinol. Metab. 89, 5810–5814 (2004).
34. Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet 368, 687 (2006).
35. Lin HH, Kao JH, Hsu HY. Least microtransfusion from mother to fetus in elective cesarean section delivery. Obstet. Gynecol. 87, 244–248 (1996).
36. Kourtis AP, Bulterys M, Nesheim SR, Lee FK. Understanding the timing of HIV transmission from mother to infant. JAMA 285, 709–717 (2001).
37. Gleicher N. Modern obstetrical and infertility care may increase the prevalence of disease. An evolutionary concept. Fertil. Steril. 79, 249–252 (2003).
38. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 365, 785–799 (2005).
39. Gleicher N, Weiner R, Vietzky M. The impact of abnormal autoimmune function on reproduction: maternal and fetal consequences. J. Autoimmunity 27, 161–165 (2006)
40. Wolfberg AJ, Lee-Parritz A, Peller AJ, Lieberman ES. Association of rheumatologic disease with preeclampsia. Obstet. Gynecol. 103, 1190–1193 (2004).
41. Skomsvoll JF, Baste V, Irgens LM, Ostensen M. The recurrence risk of adverse outcome in the second pregnancy in women with rheumatic disease. Obstet. Gynecol. 100, 1196–1202 (2002).